PSU Profiles
Last Name

Sheldon L. Holder

TitleAssistant Professor
InstitutionCollege of Medicine
Address500 University Drive Hershey, PA 17033
Phone717-531-0003 ext 289532


Fellowship, Hematology/Oncology, Vanderbilt University, 2013
Residency, Internal Medicine, Penn State M. S. Hershey Medical Center, 2010
Medical School (MD), Loma Linda University, 2007
Graduate School (PhD), Microbiology and Molecular Genetics, Loma Linda University, 2005

 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016 Jun; 21(6):708-15.
    View in: PubMed
  2. Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. 2016 Jan 26; 7(4):3662-76.
    View in: PubMed
  3. Al-Marrawi MY, Mackley HB, Ali S, Wagner H, Joshi M, Holder S, Kaag M, Mallon C, Talamo G, Drabick JJ. Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review. Clin Genitourin Cancer. 2016 Aug; 14(4):e393-9.
    View in: PubMed
  4. Yin M, Wang W, Rosenberg J, Kaag M, Joshi M, Holder S, Tuanquin L, Drabick JJ. Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review. Clin Genitourin Cancer. 2016 Apr; 14(2):e203-6.
    View in: PubMed
  5. Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, Kaag M, Talamo G, Drabick JJ. Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Clin Genitourin Cancer. 2015 Dec; 13(6):e391-5.
    View in: PubMed
  6. Al-Marrawi MY, Cream LV, Mallon CA, Holder S, Joshi M, Harvey HH, Talamo G, Drabick JJ. Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer. J Clin Oncol. 2015 Feb 10; 33(5):521-2.
    View in: PubMed
  7. Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, Drabick JJ, Joshi M. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biol Ther. 2015; 16(1):28-33.
    View in: PubMed
  8. Holder SL, Drabick J, Zhu J, Joshi M. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer. Cancer Biol Ther. 2015; 16(2):207-9.
    View in: PubMed
  9. Holder SL, Abdulkadir SA. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Curr Cancer Drug Targets. 2014; 14(2):105-14.
    View in: PubMed
  10. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem. 2007 Oct 1; 15(19):6463-73.
    View in: PubMed
  11. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan; 6(1):163-72.
    View in: PubMed
  12. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67.
    View in: PubMed
Holder's Networks
Click the "See All" links for more information and interactive visualizations!
Similar People
Same Department
Physical Neighbors